Mezzanzanica D - Search Results

1

Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.

Mezzanzanica D, Canevari S, Colnaghi MI. Mezzanzanica D, et al. Int J Clin Lab Res. 1991;21(2):159-64. doi: 10.1007/BF02591636. Int J Clin Lab Res. 1991. PMID: 1815760 Clinical Trial.

2

Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.

Ferrini S, Cambiaggi A, Cantoni C, Canevari S, Mezzanzanica D, Colnaghi MI, Moretta L. Ferrini S, et al. Among authors: mezzanzanica d. Int J Cancer Suppl. 1992;7:15-8. Int J Cancer Suppl. 1992. PMID: 1428398 Review.

3

Possible targets on carcinoma for bMAb retargeting of lymphocyte or drug cytotoxicity.

Canevari S, Mezzanzanica D, Ménard S, Ferrini S, Moretta L, Colnaghi MI. Canevari S, et al. Among authors: mezzanzanica d. Int J Cancer Suppl. 1992;7:42-4. Int J Cancer Suppl. 1992. PMID: 1428402 Review.

4

Targeting of anti-tumor responses with bispecific antibodies.

Segal DM, Qian JH, Mezzanzanica D, Garrido MA, Titus JA, Andrew SM, George AJ, Jost CR, Perez P, Wunderlich JR. Segal DM, et al. Among authors: mezzanzanica d. Immunobiology. 1992 Aug;185(2-4):390-402. doi: 10.1016/S0171-2985(11)80655-8. Immunobiology. 1992. PMID: 1452212 Review.

5

Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy.

Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Canevari S, Colnaghi MI, Segal DM. Wunderlich JR, et al. Among authors: mezzanzanica d. Int J Clin Lab Res. 1992;22(1):17-20. doi: 10.1007/BF02591388. Int J Clin Lab Res. 1992. PMID: 1633315

6

Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization.

Casalini P, Mezzanzanica D, Canevari S, Della Torre G, Miotti S, Colnaghi MI, Matzku S. Casalini P, et al. Among authors: mezzanzanica d. Int J Cancer. 1991 May 10;48(2):284-90. doi: 10.1002/ijc.2910480222. Int J Cancer. 1991. PMID: 1708366

7

Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.

Qian JH, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM. Qian JH, et al. Among authors: mezzanzanica d. J Immunol. 1991 May 1;146(9):3250-6. J Immunol. 1991. PMID: 1826709

8

Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.

Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR. Mezzanzanica D, et al. Cancer Res. 1991 Oct 15;51(20):5716-21. Cancer Res. 1991. PMID: 1833054

9

Preparation and biological characterization of conjugates consisting of ricin and a tumor-specific non-internalizing MAb.

Cogliati T, Brusa P, Canevari S, Caldera M, Mezzanzanica D, Dosio F, Cattel L, Colnaghi MI. Cogliati T, et al. Among authors: mezzanzanica d. Anticancer Res. 1991 Jan-Feb;11(1):417-21. Anticancer Res. 1991. PMID: 2018380

10

Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

Mantovani L, Ménard S, Mezzanzanica D, Miotti S, Pupa SM, Colnaghi MI. Mantovani L, et al. Among authors: mezzanzanica d. Br J Cancer Suppl. 1990 Jul;10:15-7. Br J Cancer Suppl. 1990. PMID: 2383475 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters